MedTrace Logo

Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls

NCT04273490 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2023-11-29

No results posted yet for this study

Summary

Hereditary hypophosphatemia (XLH) is a rare, inherited disease. Loss-of-function mutation in the phosphate regulating gene with homologies to endopeptidases on the X-chromosome (PHEX) results in excess fibroblast growth factor 23 (FGF23) production and manifests as rickets in children and osteomalacia in adults.

This study aims to characterize and measure pain, quality of life, muscle function, body composition, arterial stiffness, bone mineral density, geometry and microarchitecture in patients with XLH compared to age and gender-matched controls.

Conditions

  • X-linked Hypophosphatemia
  • Hereditary Hypophosphatemia

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lars Rejnmark · Dept. of Endocrinology and Internal Medicine, The Osteoporosis Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-18
Primary Completion
2022-12-20
Completion
2022-12-20

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04273490 on ClinicalTrials.gov